Pylopass™ (Lactobacillus reuteri DSM17648) is a probiotic raw material for the research of Helicobacter Pylori. OneHealth has obtained worldwide IP patent confirmation in Europe, China and Japan. The bacterial strain number is DSM 17648. In the "White Paper on Pylopass™ Lactobacillus Reuteri DSM 17648 and Helicobacter Pylori" released at the conference, OneHealth added the Sixth Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition) along with its latest research results.

Jordan said OneHealth has been cultivating and specializing in this field with scientific innovation. The new "White Paper" on Pylopass™ 2023 was released with added authoritative opinions on HP eradication added in the Sixth Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management, and with elaborations how to use Pylopass™ PRO, a Pylopass™ Live bacteria probiotic product created using freeze drying technology. It demonstrates its effectiveness compared with traditional inactivated versions of Pylopass™ solutions, where the application is broader when the former is utilized in localized products, and combined and promoted in the probiotic product category.

At present, Pylopass™ has been launched to the market, and the research result was shared with medical institutions all over China. It is expected that it will have a positive impact on popularizing the importance of Helicobacter Pylori prevention and improving the disease prevention awareness of Chinese users.